Inhibikase Therapeutics, Inc. (IKT)
IKT Stock Price Chart
Explore Inhibikase Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze IKT price movements and trends.
IKT Company Profile
Discover essential business fundamentals and corporate details for Inhibikase Therapeutics, Inc. (IKT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
23 Dec 2020
Employees
35.00
Website
https://www.inhibikase.comCEO
Mark T. Iwicki
Description
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
IKT Financial Timeline
Browse a chronological timeline of Inhibikase Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Aug 2026
EPS estimate is -$0.09.
Earnings released on 12 May 2026
EPS came in at -$0.10 matching the estimated -$0.10.
Earnings released on 26 Mar 2026
EPS came in at -$0.09 surpassing the estimated -$0.12 by +25.00%.
Earnings released on 14 Nov 2025
EPS came in at -$0.13 matching the estimated -$0.13.
Earnings released on 14 Aug 2025
EPS came in at -$0.11 falling short of the estimated -$0.09 by -22.22%.
Earnings released on 14 May 2025
EPS came in at -$0.15 falling short of the estimated -$0.11 by -36.36%.
Earnings released on 26 Mar 2025
EPS came in at -$0.63 falling short of the estimated -$0.10 by -530.00%.
Earnings released on 14 Nov 2024
EPS came in at -$0.65 falling short of the estimated -$0.38 by -71.05%.
Earnings released on 14 Aug 2024
EPS came in at -$0.66 falling short of the estimated -$0.58 by -13.79%.
Earnings released on 15 May 2024
EPS came in at -$0.73 surpassing the estimated -$0.79 by +7.59%.
Earnings released on 27 Mar 2024
EPS came in at -$0.63 surpassing the estimated -$0.78 by +19.23%, while revenue for the quarter reached $1.00 .
Earnings released on 14 Nov 2023
EPS came in at -$0.86 surpassing the estimated -$1.12 by +23.21%, while revenue for the quarter reached $79.57k .
Earnings released on 14 Aug 2023
EPS came in at -$1.11 falling short of the estimated -$0.92 by -20.65%, while revenue for the quarter reached $116.41k .
Stock split effective on 30 Jun 2023
Shares were split 1 : 6 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 16 May 2023
EPS came in at -$0.96 falling short of the estimated -$0.15 by -540.00%, while revenue for the quarter reached $64.52k .
Earnings released on 30 Mar 2023
EPS came in at -$0.20 , while revenue for the quarter reached $123.44k .
Earnings released on 14 Nov 2022
EPS came in at -$1.08 falling short of the estimated -$0.18 by -500.00%, while revenue for the quarter reached $7.29k , missing expectations by -96.35%.
Earnings released on 12 Aug 2022
EPS came in at -$1.08 falling short of the estimated -$0.19 by -468.42%, while revenue for the quarter reached $6.55k , missing expectations by -97.82%.
Earnings released on 16 May 2022
EPS came in at -$1.08 falling short of the estimated -$0.17 by -535.29%, while revenue for the quarter reached $46.03k , missing expectations by -84.66%.
Earnings released on 31 Mar 2022
EPS came in at -$1.20 falling short of the estimated -$0.17 by -605.88%, while revenue for the quarter reached $1.94k , missing expectations by -99.35%.
Earnings released on 15 Nov 2021
EPS came in at -$1.08 falling short of the estimated -$0.14 by -671.43%, while revenue for the quarter reached $328.46k , beating expectations by +9.49%.
Earnings released on 16 Aug 2021
EPS came in at -$1.32 falling short of the estimated -$0.38 by -247.37%, while revenue for the quarter reached $1.36m , beating expectations by +354.35%.
IKT Stock Performance
Access detailed IKT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
